Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
The Pharma Data
AUGUST 9, 2020
Pivotal phase III stud y of etrolizumab in Crohn’s disease is ongoing. Roche is studying additional investigational medicines in inflammatory bowel diseases. In the HIBISCUS I induction study, in people without prior anti-tumour necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint.
52 
Let's personalize your content